Jade Biosciences (JBIO): Bellevue Group AG added to its stake +160K shares

3.5M

Shares reported · +160K vs prior quarter

1.2%

Disclosed portfolio weight

$49.2M

Reported value

Holdings as of

Mar 31, 2026

Filed

May 15, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Mar 31, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 31, 2026, the Board of Directors (the “Board”) of Jade Biosciences, Inc. (the “Company”) approved the Jade Biosciences, Inc. 2026 Employment Inducement Stock Incentive Plan (the “2026 Inducement Plan”).”
2. Apr 18, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 18, 2026, the Board of Directors of Jade Biosciences, Inc. (the “Company”) appointed Andrew King, BVMS, Ph.D. as the Company’s President, Research & Development, effective as of April 18, 2026.”
3. May 7, 2026Company filing · Form 8-K · ResultsReported its results

What came next

1. Jun 8, 2026Company filing · Form 8-K · Bylaws or charter, Shareholder voteChanged its bylaws, charter or fiscal year, and held a shareholder vote
2. Jun 25, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On June 25, 2026, the Board of Directors (the “Board”) of Jade Biosciences, Inc. (the “Company”) appointed Mark Eisner, M.D., M.P.H., to serve as a Class I director of the Company, to hold office until the Company’s 2028 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier resignation, death or removal.”
3. Jun 29, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
4. Aug 10, 2026Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Jade Biosciences

For Jade Biosciences, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its JBIO page.

How this filing works

• SEC Form 13F

Other disclosures at Jade Biosciences

• SEC Schedule 13GOct 28, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRFeb 17, 2026
• SEC Form 13F-HRFeb 17, 2026
• SEC Form 13F-HRFeb 13, 2026

Everything OQRO holds on this company is on its JBIO page.